R

REGENXBIO

RGNX

13.370
USD
-0.92
(-6.44%)
مفتوح الان
حجم التداول
11,561
الربح لكل سهم
0
العائد الربحي
0
P/E
-2
حجم السوق
465,566,431
أصول ذات صلة
B
BLUE
-0.06000
(-5.26%)
1.08000 USD
B
BMRN
0.270
(0.32%)
84.620 USD
C
CRSP
-2.450
(-4.28%)
54.840 USD
E
EDIT
-0.28500
(-5.26%)
5.13500 USD
N
NTLA
-1.100
(-4.19%)
25.130 USD
S
SGMO
-0.09690
(-12.11%)
0.70340 USD
الأخبار المقالات

العنوان: REGENXBIO

القطاع: Healthcare
الصناعة: Biotechnology
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.